艾司氯胺酮治疗难治性抑郁症研究新进展
New Progress in the Treatment of Refractory Depression with Esticketamine
DOI: 10.12677/ACM.2022.125592, PDF,  被引量   
作者: 孙诗立：济宁医学院，山东 济宁；范 勇, 王春霞：青岛市精神卫生中心，山东 青岛
关键词: 艾司氯胺酮；难治性抑郁症；NMDA；BDNF；Esticketamine； Treatment-Resistant Depression； NMDA； BDNF
摘要: 艾司氯胺酮作为一种新型抗抑郁药物，不同于传统抗抑郁药物的作用机制，主要通过拮抗N-甲基-D-天冬氨酸受体，激活α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体，增加脑源性神经营养因子(brain-derived neurotrophic factor, BDNF)及单胺类神经递质的释放，促进突触可再生等机制而发挥抗抑郁作用。服用艾司氯胺酮可快速缓解难治性抑郁症抑郁症状，迅速消除自杀意图，患者耐受性良好。本文就艾司氯胺酮治疗难治性抑郁症的作用机制及疗效做一综述。
Abstract: Asketamine, as a new antidepressant, is different from traditional antidepressants in its mecha-nism of action, mainly through antagonizing n-methyl-D-aspartic acid receptor, activating α-amino- 3-hydroxy-5-methyl-4-isooxazolpropionic acid receptor. It increases the release of brain-derived neurotrophic factor (BDNF) and monoamine neurotransmitter, promotes synaptic regeneration and other mechanisms to exert antidepressant effects. The administration of esketamine can quickly relieve the depressive symptoms of refractory depression and quickly eliminate the suicidal inten-tion, which is well tolerated by patients. This article reviews the mechanism and efficacy of esketa-mine in the treatment of refractory depression.
文章引用：孙诗立, 范勇, 王春霞. 艾司氯胺酮治疗难治性抑郁症研究新进展[J]. 临床医学进展, 2022, 12(5): 4090-4095. https://doi.org/10.12677/ACM.2022.125592

参考文献

[1] 张钰群, 袁勇贵. 2020年抑郁症研究进展回顾[J]. 中华医学信息导报, 2021, 36(4): 11-12.
[2] Al-Harbi, K.S. (2012) Treatment-Resistant Depression: Therapeutic Trends, Challenges, and Future Directions. Patient Prefer Adherence, 6, 369-388. [Google Scholar] [CrossRef] 
[3] Trevino, K., McClintock, S.M., McDonald Fischer, N., et al. (2014) Defining Treatment-Resistant Depression: A Comprehensive Review of the Literature. Annals of Clinical Psychi-atry, 26, 222-232.
[4] Vollenweider, F.X., Leenders, K.L., Oye, I., et al. (1997) Differential Psychopathology and Patterns of Cerebral Glucose Utilisation Produced by (S)- and (R)-Ketamine in Healthy Volunteers Using Positron Emis-sion Tomography (PET). European Neuropsychopharmacology, 7, 25-38. [Google Scholar] [CrossRef] 
[5] 余乐, 王清秀. 麻醉药抗抑郁作用的研究进展[J]. 同济大学学报(医学版), 2021, 42(4): 574-580.
[6] Mahase, E. (2021) Depression: EU Approves Expanded Use of Es-ketamine for Rapid Reduction of Symptoms. BMJ, 372, n398. [Google Scholar] [CrossRef] [PubMed]
[7] Swainson, J., Thomas, R.K., Archer, S., et al. (2019) Esketamine for Treatment Resistant Depression. Expert Review of Neurothera-peutics, 19, 899-911. [Google Scholar] [CrossRef] [PubMed]
[8] Castrén, E. and Kojima, M. (2017) Brain-Derived Neurotrophic Factor in Mood Disorders and Antidepressant Treatments. Neurobiology of Disease, 97, 119-126. [Google Scholar] [CrossRef] [PubMed]
[9] Garcia, L.S., Comim, C.M., Valvassori, S.S., et al. (2008) Acute Administration of Ketamine Induces Antidepressant-Like Effects in the Forced Swimming Test and Increases BDNF Levels in the Rat Hippocampus. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32, 140-144. [Google Scholar] [CrossRef] [PubMed]
[10] Derkach, V.A., Oh, M.C., Guire, E.S., et al. (2007) Regulatory Mechanisms of AMPA Receptors in Synaptic Plasticity. Nature Reviews Neuroscience, 8, 101-113. [Google Scholar] [CrossRef] [PubMed]
[11] Holz, A., Mülsch, F., Schwarz, M.K., et al. (2019) Enhanced mGlu5 Signal-ing in Excitatory Neurons Promotes Rapid Antidepressant Effects via AMPA Receptor Activation. Neuron, 104, 338-352.e7. [Google Scholar] [CrossRef] [PubMed]
[12] Zanos, P., Moaddel, R., Morris, P.J., et al. (2016) NMDAR In-hibition-Independent Antidepressant Actions of Ketamine Metabolites. Nature, 533, 481-486. [Google Scholar] [CrossRef] [PubMed]
[13] Pozzi, L., Pollak Dorocic, I., Wang, X., et al. (2014) Mice Lacking NMDA Receptors in Parvalbumin Neurons Display Normal Depression-Related Behavior and Response to Antidepres-sant Action of NMDAR Antagonists. PLoS ONE, 9, e83879. [Google Scholar] [CrossRef] [PubMed]
[14] Zanos, P. and Gould, T.D. (2018) Mechanisms of Ketamine Ac-tion as an Antidepressant. Molecular Psychiatry, 23, 801-811. [Google Scholar] [CrossRef] [PubMed]
[15] Aleksandrova, L.R., Phillips, A.G. and Wang, Y.T. (2017) Antidepres-sant Effects of Ketamine and the Roles of AMPA Glutamate Receptors and Other Mechanisms beyond NMDA Receptor Antagonism. Journal of Psychiatry & Neuroscience, 42, 222-229. [Google Scholar] [CrossRef] [PubMed]
[16] Cavalleri, L., Merlo Pich, E., Millan, M.J., et al. (2018) Ketamine Enhanc-es Structural Plasticity in Mouse Mesencephalic and Human iPSC-Derived Dopaminergic Neurons via AMPAR-Driven BDNF and mTOR Signaling. Molecular Psychiatry, 23, 812-823. [Google Scholar] [CrossRef] [PubMed]
[17] Murrough, J.W., Iosifescu, D.V., Chang, L.C., et al. (2013) Antidepres-sant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. The American Journal of Psychiatry, 170, 1134-1142. [Google Scholar] [CrossRef] [PubMed]
[18] Lee, E.E., Della Selva, M.P., Liu, A., et al. (2015) Ketamine as a Novel Treatment for Major Depressive Disorder and Bipolar Depression: A Systematic Review and Quantitative Meta-Analysis. General Hospital Psychiatry, 37, 178-184. [Google Scholar] [CrossRef] [PubMed]
[19] Yang, C., Shirayama, Y., Zhang, J.C., et al. (2015) R-Ketamine: A Rapid-Onset and Sustained Antidepressant without Psychotomimetic Side Effects. Translational Psychi-atry, 5, e632. [Google Scholar] [CrossRef] [PubMed]
[20] Yang, C., Kobayashi, S., Nakao, K., et al. (2018) AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine. Biological Psychiatry, 84, 591-600. [Google Scholar] [CrossRef] [PubMed]
[21] Murrough, J.W., Abdallah, C.G. and Mathew, S.J. (2017) Targeting Glutamate Signalling in Depression: Progress and Prospects. Nature Reviews Drug Discovery, 16, 472-486. [Google Scholar] [CrossRef] [PubMed]
[22] Singh, J.B., Fedgchin, M., Daly, E., et al. (2016) Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. Biological Psychiatry, 80, 424-431. [Google Scholar] [CrossRef] [PubMed]
[23] Daly, E.J., Singh, J.B., Fedgchin, M., et al. (2018) Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry, 75, 139-148. [Google Scholar] [CrossRef] [PubMed]
[24] Canuso, C.M., Singh, J.B., Fedgchin, M., et al. (2018) Ef-ficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Pa-tients at Imminent Risk for Suicide: Results of a Double- Blind, Randomized, Placebo-Controlled Study. The American Journal of Psychiatry, 175, 620-630. [Google Scholar] [CrossRef] [PubMed]
[25] Grunebaum, M.F., Galfalvy, H.C., Choo, T.H., et al. (2018) Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. The American Journal of Psychiatry, 175, 327-335. [Google Scholar] [CrossRef] [PubMed]
[26] Kim, J., Farchione, T., Potter, A., et al. (2019) Esketamine for Treatment-Resistant Depression—First FDA-Approved Antidepressant in a New Class. The New England Journal of Medicine, 381, 1-4. [Google Scholar] [CrossRef] 
[27] 李普乐, 康霞, 吕爽, 等. 艾司氯胺酮用于抑郁症治疗的研究进展[J]. 中华实用诊断与治疗杂志, 2021, 35(7): 750-752.
[28] Bahr, R., Lopez, A. and Rey, J.A. (2019) Intranasal Esketamine (Spravato(TM)) for Use in Treatment-Resistant Depression in Conjunction with an Oral Antidepressant. PT, 44, 340-375.
[29] Short, B., Fong, J., Galvez, V., et al. (2018) Side-Effects Associated with Ketamine Use in Depres-sion: A Systematic Review. The Lancet Psychiatry, 5, 65-78. [Google Scholar] [CrossRef] 
[30] Bossaller, N.A. and Shelton, R.C. (2020) Real-World Ap-proach to Managing Dysgeusia Following the Use of Esketamine Nasal Spray: A Case Report. Annals of General Psy-chiatry, 19, 13. [Google Scholar] [CrossRef] [PubMed]
[31] Dold, M., Bartova, L. and Kasper, S. (2020) Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Sec-ond-Generation Antipsychotic Treatment. International Journal of Neuropsychopharmacology, 23, 440-445. [Google Scholar] [CrossRef] [PubMed]
[32] Correia-Melo, F.S., Argolo, F.C., Araújo-de-Freitas, L., et al. (2017) Rapid Infusion of Esketamine for Unipolar and Bipolar Depression: A Retrospective Chart Review. Neuropsychiatric Disease and Treatment, 13, 1627-1632. [Google Scholar] [CrossRef] 
[33] Sanacora, G., Frye, M.A., McDonald, W., et al. (2017) A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry, 74, 399-405. [Google Scholar] [CrossRef] [PubMed]
[34] 冯若冰, 肖乐, 胡永东. 氯胺酮抗抑郁治疗临床研究进展[J]. 北京医学, 2019, 41(7): 595-597.
[35] 李嘉, 韩芳. 新型抗难治性抑郁症药艾司氯胺酮研究进展[J]. 牡丹江医学院学报, 2021, 42(5): 103-106.
[36] Leal, G.C., Bandeira, I.D., Correia-Melo, F.S., et al. (2021) Intravenous Arketamine for Treatment-Resistant Depression: Open-Label Pilot Study. European Archives of Psychiatry and Clinical Neuroscience, 271, 577-582. [Google Scholar] [CrossRef] [PubMed]
[37] 范妮. 氯胺酮抗抑郁的临床研究[J]. 四川精神卫生, 2021, 34(3): 193-196.
[38] Cullen, K.R., Amatya, P., Roback, M.G., et al. (2018) Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study. Journal of Child and Adolescent Psychopharmacology, 28, 437-444. [Google Scholar] [CrossRef] [PubMed]

为你推荐